Hepatocellular carcinoma (HCC), the most common histological subtype of liver cancer, is the third‐leading cause of cancer‐related death worldwide.[1] Although patients with resectable HCC can be treated with surgical resection or liver transplantation, and patients with advanced unresectable HCC can be treated with sorafenib, these tumors are prone to recurrence after treatment.[2] Despite advances in immune checkpoint blockade (ICB) therapy, such as anti‐PD‐1/L1 antibodies, treatment resistance remains a major obstacle, with over 90% of deaths attributed to metastasis or refractory disease. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.